STAT

APRIL 27, 2023

Will Eli Lilly usurp Johnson & Johnson? We also discuss the latest news in the life sciences, including Lilly’s surging business, a pair of new drug approvals, and a novel idea in Alzheimer’s disease. Is a specter haunting Europe? And what does “Vowst” call to mind? Read the rest…

70

70

STAT

JANUARY 26, 2024

Sanders, who has threatened to subpoena the chief executive officers at Merck and Johnson & Johnson over their refusal to testify at a hearing on why drug prices are higher in the U.S. business, who is responsible for U.S. pricing, testify. The trade group for generic drug companies in the U.S.

96

96

STAT

FEBRUARY 6, 2024

Clear blue skies and rays of sunshine are enveloping the Pharmalot campus, where the official mascots are busy waking the neighbors and assorted other creatures are moseying about. Top of the morning to you, and a fine one it is. You can see the results as you scroll down. Settings are adjusted to accept postcards and telegrams.

Insurance 85

Insurance 85

Pharmaceutical Technology

APRIL 19, 2023

Johnson & Johnson (J&J) has reported a 5.6% J&J’s pharmaceutical business recorded a 4.2% increase in sales to $24.75bn in the first quarter (Q1) of 2023, up from $23.4bn during the corresponding quarter of 2022. The company reported a net earnings loss of $68m, down by 101.3% from $5.15bn in Q1 2022.

52

52

Fierce Pharma

JULY 24, 2023

With Johnson & Johnson’s consumer health spinoff in the rearview, J&J is taking its hands off the Kenvue steering wheel to focus on its own business—and offering investors an incentive to t | Leveraging a stock exchange offer—also known as a split-off—J&J aims to reduce its stake in Kenvue by roughly 80%, the company said Monday.

68

68

pharmaphorum

SEPTEMBER 30, 2022

Trusted Johnson & Johnson brands including Tylenol, Aveeno, Neutrogena, Listerine, and Band-Aid are set to fall under the new, independent company name in a next-chapter move of repurposing and modernisation. Johnson & Johnson’s Consumer Health segment reported a revenue of $14.6 billion in the Full-Year 2021.

52

52

Pharmaceutical Technology

OCTOBER 19, 2022

Johnson & Johnson (J&J) has reported sales of $23.79bn in the third quarter (Q3) of 2022, indicating an increase of 1.9% Johnson & Johnson CEO Joaquin Duato said: “Our third quarter performance demonstrates our continued strength and resilience across all three of our businesses. in Q3 2021.

52

52

STAT

SEPTEMBER 15, 2022

Rise and shine, everyone, another busy day is on the way. We always enjoy your tips and insights… Johnson & Johnson announced a stock buyback of up to $5 billion, joining a rush of U.S. So, time to get cracking. Hope you have a smashing day, and do stay in touch.

75

75

Pharma Marketing Network

DECEMBER 17, 2021

Big pharma has compelling reasons to change the way business gets done. Johnson & Johnson was one of the first major companies to make a public commitment to the SDGs in 2016. The wave of interest in sustainability follows the value chain from top-tier pharmaceutical companies to their suppliers of every size. What’s Next?

Pharmaceutical Companies 103

Pharmaceutical Companies Pharmaceutical Companies Communication 103

STAT

NOVEMBER 1, 2023

And what better way to make the time fly than to keep busy. The FDA approved Amgen’s biosimilar version of Johnson & Johnson’s blockbuster psoriasis treatment, Stelara, for multiple inflammatory diseases , Reuters says. The middle of the week is upon us. Have heart, though.

FDA 93

FDA 93

pharmaphorum

DECEMBER 4, 2022

Amgen and Sanofi have said they may make cash-only offers for Horizon Therapeutics, which confirmed it was in talks with potential buyers last week, but Johnson & Johnson has ruled itself out of the running. J&J’s statement indicated it may be prepared to come back to the table at a later date.

98

98

pharmaphorum

FEBRUARY 11, 2022

Ipsen has started exclusive negotiations that could see its global consumer health business sold to fellow French pharma company Mayoly Spindler later this year. Ipsen’s specialty pharma business grew almost 13% to €2.6 The post Ipsen plans sale of consumer health business for €350m appeared first on. billion last year.

102

102

pharmaphorum

JUNE 1, 2021

At this year’s BIO-Europe Spring Digital , pharmaphorum founder Dr. Paul Tunnah participated in an ‘In conversation’ chat with Nerida Scott, head of Johnson & Johnson Innovation, EMEA. Nerida discussed the latest trends in healthcare and how they’ve influenced Johnson & Johnson Innovation’s (JJI’s) approach to collaboration.

Communication 52

Communication 52

Pharmaceutical Technology

JULY 7, 2022

So, what will Boris Johnson, a UK Prime Minister defenestrated by his own MPs, be most remembered for? Johnson would hope the pillars of his legacy are his oft repeated slogans of ‘getting Brexit done’ and ‘getting the country through Covid’. Boris was bad for business. Investors crave reliability and predictability.

52

52

pharmaphorum

APRIL 20, 2022

Teva’s long haul to a turnaround of its business has been dealt a blow by the FDA, which has just declined to approve the company’s long-acting formulation of schizophrenia drug risperidone.

FDA 98

FDA 98

PQA

MAY 3, 2024

Integrating Specialty Pharmacy Walgreens will launch a variety of new services as a part of its newly integrated specialty pharmacy business. The discussion covered where there’s an opportunity to start thinking about strategic partnerships and to ensure that its solutions are equitable, meaningful and timely for its associates.

Specialty Pharmacies 52

Specialty Pharmacies 52

pharmaphorum

MAY 12, 2022

In February, Johnson & Johnson and the ‘big three’ US pharma wholesalers – McKesson, Cardinal Health, and AmerisourceBergen – said they were close to finalising a $26 billion settlement to extricate themselves from opioid litigation and fund projects to prevent and treat opioid addiction.

97

97

pharmaphorum

MAY 12, 2022

Johnson & Johnson has appointed Thibaut Mongon as the chief executive of its consumer health division, which is scheduled to be spun off into a listed company by the end of 2023. The post J&J names CEO of its consumer health unit ahead of spinout appeared first on.

52

52

pharmaphorum

NOVEMBER 14, 2021

After decades of a diversified healthcare business model, Johnson & Johnson has announced it plans to split off its consumer health division from its pharma and medical device operations. Gorsky said that the decision is the “best way to…drive profitable growth” for all J&J’s business units.

57

57

pharmaphorum

JUNE 10, 2021

Among the participating companies are Bayer, Biogen, Gedeon Richter, Janssen from Johnson&Johnson, Roche, STADA, Samsung Biologics, Pfizer. Request business program via the link. . The post Pharmaceutical Manufacturing and Packaging Congress 2021 appeared first on.

Packaging 52

Packaging Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

JUNE 3, 2021

In the newly-created role, Goldstein will oversee the execution of 4,500 projects per year across The Bloc’s US client business. Clients include Johnson & Johnson, Oreo, Coca-Cola, Novartis, Diageo, eBay, GlaxoSmithKline, Time Warner, and Marvel. In 2021, the agency celebrated 21 years of business.

52

52

European Pharmaceutical Review

AUGUST 21, 2023

percent over Q2 2023, moving up to first position in the list and displacing Johnson & Johnson from its top spot for the first time even though it reported a 6.8 percent increase in market capitalisation,” commented Alison Labya, MSc, Business Fundamentals Analyst at GlobalData. billion to revenue in Q2 2023.

Vaccines 86

Vaccines FDA 86

pharmaphorum

SEPTEMBER 6, 2021

As part of the process, its generics subsidiary business would be declared insolvent, but the remainder of the company would be able to continue as normal without the threat of litigation. billion settlement for Purdue Pharma – which may still be challenged on appeal. Other opioid litigation continues elsewhere, meanwhile.

Documentation 98

Documentation Immunization 98

Pharma Marketing Network

JULY 25, 2023

Sponsorships are a powerful tool that businesses can use to amplify healthcare awareness and education. By partnering with healthcare organizations, businesses can reach a wider audience with important health information and help to promote healthy lifestyles. Set clear goals.

FDA 52

FDA 52

Viseven

OCTOBER 3, 2023

Viseven and Veeva have been partners for many years, providing advanced technology and content expertise to pharma and life sciences businesses and agencies of all sizes, and it was a big honor and privilege for the Viseven team to be at the event and make its own contribution to the evolution of biopharma digital marketing.

52

52

European Pharmaceutical Review

DECEMBER 6, 2022

Johnson & Johnson maintained its top position, despite a market capitalisation loss of 8 percent, followed by Eli Lilly, Roche and Pfizer. GlobalData’s Pharmaceutical Intelligence Center Companies Database found that 16 of the 20 top biopharmaceutical companies indicated a decline in quarter-on-quarter (QoQ) market capitalisation.

Vaccines 78

Vaccines FDA 78

PharmaShots

MAY 10, 2023

billion, followed by Johnson & Johnson and EssilorLuxottica. The company has divided its business into four segments i.e., Imaging, Diagnostics, Varian, and Advanced Therapies. The company operates under three business segments Cardiac and Vascular, Medical Care Solutions, and Blood and Cell Technologies.

Nursing Homes 40

Nursing Homes Hospitals FDA Communication 40

pharmaphorum

NOVEMBER 2, 2022

Johnson & Johnson’s $16.6 billion takeover offer for cardiac pump manufacturer Abiomed looks set to be the largest medtech acquisition of the year, and other buyers are unlikely to enter a bidding war for the business.

52

52

pharmaphorum

OCTOBER 20, 2020

It’s not clear which vaccine will be involved in the study – there are several in the last stages of clinical development and the UK government has orders for candidates from AstraZeneca, Pfizer/BioNTech, Novavax, Valneva, Sanofi/GSK and Johnson & Johnson. No financial details of the contract with hVIVO were disclosed.

Vaccines 98

Vaccines 98

pharmaphorum

JUNE 28, 2021

Johnson & Johnson has shaken off another lingering liability claim in the US, agreeing a $263 million settlement with New York to resolve lawsuits focused on its role in the US opioid crisis. J&J also said in a statement that it committed to exiting its opioid painkiller business altogether last year.

52

52

pharmaphorum

JANUARY 27, 2021

The safety of our employees and business continuity remain of paramount importance. The plant was visited by Prime Minister Boris Johnson last month along with Wrexham’s conservative MP Sarah Atherton, shortly after the UK government reserved one fill and finish production line at the unit for its exclusive use for 18 months.

Vaccines 98

Vaccines Packaging Hospitals 98

pharmaphorum

JANUARY 13, 2023

Serving as a financial partner to top-tier, early-to-mid stage portfolio companies, the fund also supports future efforts for business development and M&A opportunities within Sanofi.

Documentation 52

Documentation Vaccines 52

Pharma Marketing Network

MAY 17, 2021

He brings a commitment to not accept the status quo to drive innovative thinking and cultural change that delivers business results, achieves efficiencies, and builds a competitive advantage through award-winning customer experiences. billion acquisition of Synthes and was chairman of the Digital Acceleration team for the MD&D sector.

52

52

STAT

JULY 6, 2023

As for us, we are busy with the usual sorts of things. The petitioners are 21 companies from five corporate families — AstraZeneca, GE Healthcare Technologies, Johnson & Johnson, Pfizer. nationals injured by acts of international terrorism.

Vaccines 65

Vaccines Pharmaceutical Companies Pharmaceutical Companies FDA 65

pharmaphorum

JUNE 15, 2021

Those include an Applied Genetic Technologies candidate which recently reported positive results in a phase 1/2 trial, MeiraGTx therapy – partnered with Johnson & Johnson – with phase 1/2 data in hand and phase 3 in preparation, and 4D Molecular Therapeutics therapy with a phase 1/2 readout due in the second half of this year.

FDA 104

FDA 104

pharmaphorum

SEPTEMBER 2, 2021

A US federal judge has approved a bankruptcy settlement for Purdue Pharma that grants the Sackler family that owned the business immunity from any further civil lawsuits accusing them of contributing to opioid epidemic – to the consternation of campaigners. ” Other opioid litigation continues elsewhere, meanwhile.

Immunization 104

Immunization 104

pharmaphorum

MARCH 29, 2021

Throughout her career she has worked with industry leaders including AstraZeneca, Pfizer, Lilly, Sanofi, GSK, Johnson & Johnson, Janssen, Merck, Genentech, and the Mayo Clinic. We need to find new ways of connecting with busy healthcare professionals. Today’s health environment is complex, fast paced and demanding.

Mayo Clinic 67

Mayo Clinic Pharmaceutical Companies Pharmaceutical Companies Hospitals 67